首页> 外文期刊>The Journal of Urology >Urethral recurrence after radical radiotherapy for bladder cancer.
【24h】

Urethral recurrence after radical radiotherapy for bladder cancer.

机译:膀胱癌根治性放疗后尿道复发。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Following cystectomy for bladder cancer, orthotopic reconstruction may result in a decreased risk of urethral recurrence compared to cutaneous diversion. We evaluate the rate of urethral recurrence after radical external beam radiotherapy. MATERIALS AND METHODS: We reviewed the records of 214 men who had received radical radiotherapy at a single center from 1990 to 1995. Patients treated with chemotherapy were excluded from study. RESULTS: A total of 214 men (median age 69 years, range 39 to 86) underwent radical radiotherapy for cure. Tumor stages were T1 in 7%, T2 in 41%, T3 in 42% and T4a in 10% of the patients. Median followup was 32 months (range 1 month to 8.4 years) and 5-year survival rate was 30%. Urethral recurrence developed in 7 (3.2%) cases and was detected within 18 months (median 10 months, range 3 months to 5 years) of followup in 5. In 2 of these 7 cases recurrence developed in the prostatic urethra, and when these 2 cases were excluded from analysis the recurrence rate decreased to 2.3%. A total of 64 men completed 5-year followup, with a 4.7% rate of urethral recurrence (3.1% excluding prostatic urethral recurrence). Multifocal disease, bladder neck involvement, prostatic disease and cis were possible risk factors for urethral recurrence. CONCLUSIONS: The risk of urethral recurrence after radical radiotherapy for transitional cell carcinoma of the bladder is comparable with that reported after orthotopic reconstruction. It is not possible to exclude completely that men at higher risk were offered cystectomy, but the data are consistent with the suggestion that continued contact with urine may be protective.
机译:目的:膀胱癌膀胱切除术后,与皮肤转移相比,原位重建可降低尿道复发的风险。我们评估了根治性外照射后的尿道复发率。材料与方法:我们回顾了1990年至1995年在同一中心接受过放射治疗的214名男性的记录。接受化学疗法治疗的患者被排除在研究之外。结果:共有214名男性(中位年龄69岁,范围39至86)接受了根治性放射治疗。肿瘤分期为:T1占7%,T2占41%,T3占42%,T4a占10%。中位随访时间为32个月(1个月至8。4年),5年生存率为30%。尿道复发发生在7(3.2%)例中,在5例随访中的18个月(中位数为10个月,范围为3个月至5年)内被发现。在这7例病例中,有2例在前列腺尿道中复发,而当这2例发生时病例被排除在分析之外,复发率降至2.3%。共有64名男性完成了5年的随访,尿道复发率为4.7%(不包括前列腺尿道复发为3.1%)。多灶性疾病,膀胱颈受累,前列腺疾病和顺式可能是尿道复发的危险因素。结论:根治性放射治疗膀胱移行细胞癌后尿道复发的风险与原位重建后的风险相当。不可能完全排除高危男性接受膀胱切除术的可能性,但数据与继续接触尿液可能具有保护作用的暗示是一致的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号